Qurexa Logo
Qurexa

Trust. Care. Deliver.

Back to Blog & Insights
Health

Children as young as five can now have this gene-editing treatment

Qurexa Editorial Team2 November 20266 min read 0 0
Children as young as five can now have this gene-editing treatment

What happened

The UK's medicines regulator has widened who is allowed to have a gene-editing treatment for two serious blood conditions. On 30 October 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) said that a treatment called Casgevy can now be given to children aged five and over. Until now, it was only licensed for people aged 12 and over. The MHRA granted the change on 29 October 2026. Casgevy's full medical name is exagamglogene autotemcel. It is made by Vertex Pharmaceuticals (Europe) Ltd. It is licensed for two conditions: - Severe sickle-cell disease. This is where red blood cells become stiff and curved, instead of soft and round. They can block small blood vessels, which causes episodes of severe pain known as a crisis. - Transfusion-dependent beta-thalassaemia. This is where the body cannot make enough healthy haemoglobin, the part of blood that carries oxygen. People with it often need regular blood transfusions for life. Both conditions are inherited, which means they are passed down through families. Both last a lifetime. Julian Beach, MHRA Executive Director of Operations, said: "Severe sickle cell disease and beta-thalassemia are serious, lifelong conditions that in some cases can be fatal." He added that the MHRA will keep watching how safe and how effective the treatment is now that more children can have it.

Why this matters

Sickle-cell disease and thalassaemia are not rare in the UK. The NHS says sickle-cell disease is particularly common in people with an African or Caribbean family background. Thalassaemia is more common in people whose families come from the Mediterranean, South Asia, South East Asia and the Middle East. For a child, these conditions can shape daily life. A sickle-cell crisis can mean days in hospital on strong painkillers. Regular transfusions mean regular hospital appointments, often every few weeks, for years. Lowering the age limit from 12 to 5 matters for a simple reason. It gives families and their medical teams the option to consider the treatment earlier in childhood, rather than waiting until the teenage years. It is important to be clear about what this decision is, and what it is not. A licence from the MHRA means a medicine has been checked and can be supplied in the UK. It does not by itself decide who receives it on the NHS. Funding for very expensive treatments is decided separately. So this announcement widens who is eligible in law, not automatically who gets treated next month.

What the evidence actually says

The MHRA said it approved the wider age range after a careful assessment of the evidence on the treatment's safety, quality and effectiveness. The regulator did not publish trial figures in its announcement, so we are not going to invent any here. What the MHRA did set out is how the treatment works, and that part is worth understanding. Casgevy is not a tablet or a regular injection. It is a one-off procedure that uses the child's own cells. Stem cells are collected from the child's bone marrow. In a laboratory, a gene-editing tool is used to change those cells so that the body makes a different, healthier form of haemoglobin. The edited cells are then put back into the child through a drip. Before the edited cells go back in, the child needs what doctors call conditioning treatment. This clears space in the bone marrow. It is demanding, and children may need to stay in hospital afterwards while their blood counts recover. The MHRA lists side effects including feeling sick, tiredness, fever and a raised risk of infection. That last one matters, because the conditioning stage temporarily weakens the body's defences. So the honest picture is this. The treatment offers the possibility of a lasting change from a single procedure. But it is a serious procedure with real risks, not a simple fix. That is exactly why the decision about whether it is right for any one child belongs to that child's family and specialist team.

Practical advice

If this news affects your family, here are sensible next steps. 1. Speak to your specialist team first. Sickle-cell disease and thalassaemia are looked after by specialist haematology services. Your consultant is the right person to tell you whether this treatment is a realistic option for your child, and what the local route would be. 2. Write your questions down before the appointment. Useful ones include: Is my child suitable? What would the hospital stay involve? What are the risks for us specifically? What are the alternatives? What happens if we decide to wait? 3. Do not stop any current treatment. If your child takes medicines, has regular transfusions or follows a care plan, keep going as normal unless your team tells you otherwise. A change in the law about who can be treated is not a reason to change anything today. 4. Be careful with what you read online. News like this attracts a lot of exaggerated claims. Stick to the MHRA, the NHS website and recognised patient charities. 5. Ask about support. Living with a long-term condition is tiring for the whole family. Specialist nurses can often point you towards practical and emotional support you did not know existed.

What to know

The MHRA has extended the licence for the gene-editing treatment Casgevy so it can be used in children aged five and over, instead of 12 and over. The change was granted on 29 October 2026 and announced on 30 October 2026. It covers severe sickle-cell disease and transfusion-dependent beta-thalassaemia. The treatment edits a child's own bone marrow stem cells and returns them in a single procedure. It requires conditioning treatment first, and a possible hospital stay. Known side effects include feeling sick, tiredness, fever and a higher risk of infection. A licence is a regulatory step. It is not the same as a decision about NHS funding, and it is not advice that any individual child should have the treatment. If your family is affected, the specialist haematology team is the right place to start. Sources: GOV.UK (Medicines and Healthcare products Regulatory Agency), "MHRA approves gene-editing treatment for children aged five and over with serious inherited blood disorders", 30 October 2026, https://www.gov.uk/government/news/mhra-approves-gene-editing-treatment-for-children-aged-five-and-over-with-serious-inherited-blood-disorders; NHS, "Sickle cell disease", https://www.nhs.uk/conditions/sickle-cell-disease/; NHS, "Thalassaemia", https://www.nhs.uk/conditions/thalassaemia/. This article is for general information and does not replace advice from a doctor, pharmacist or other qualified healthcare professional.

#sickle cell#thalassaemia#gene therapy#MHRA#childrens health#NHS

Related articles